Skip to content
Journal article

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: A pilot study

Ringe J, Dorst A, Faber H, Kipshoven C, Rovati L, Setnikar I...(+6 more)

Rheumatology International, vol. 25, issue 4 (2005) pp. 296-300

  • 10

    Readers

    Mendeley users who have this article in their library.
  • 7

    Citations

    Citations of this article.
  • N/A

    Views

    ScienceDirect users who have downloaded this article.
Sign in to save reference

Abstract

In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.

Find this document

Get full text

Cite this document

Choose a citation style from the tabs below